The world's biggest marijuana stock is surging after a $4 billion investment from the maker of Corona (CGC)


Canopy Growth, the largest publicly traded marijuana company, fell short of Wall Street’s earnings expectations on Tuesday, but news of a new investment overshadowed the larger-than-expected loss. 

Shares of the Canadian company surged more than 50% in early trading Wednesday after Canopy announced Constellation Brands — the $42 billion company behind Corona — had upped its investment in the marijuana grower by $4 billion and now owns a 38% stake.

Canopy Growth said in a press release that the proceeds will allow it to "strategically build and/or acquire key assets needed to establish global scale in the nearly 30 countries pursuing a federally permissible medical cannabis program, while also rapidly laying the global foundation needed for new recreational cannabis markets."

RELATED: Legal recreational marijuana sold in California

23 PHOTOS
Legal recreational marijuana sold in California
See Gallery
Legal recreational marijuana sold in California
Customers buy recreational marijuana at the MedMen store in West Hollywood, California U.S. January 2, 2018. REUTERS/Lucy Nicholson
Marijuana is displayed for sale at the MedMen store in West Hollywood, California U.S. January 2, 2018. REUTERS/Lucy Nicholson
A customer browses marijuana products for sale at the MedMen store in West Hollywood, California U.S. January 2, 2018. REUTERS/Lucy Nicholson
Customers queue for recreational marijuana outside the MedMen store in West Hollywood, California U.S. January 2, 2018. REUTERS/Lucy Nicholson
A customer browses screens displaying recreational marijuana products for sale at the MedMen store in West Hollywood, California U.S. January 2, 2018. REUTERS/Lucy Nicholson
A woman holds marijuana for sale at the MedMen store in West Hollywood, California U.S. January 2, 2018. REUTERS/Lucy Nicholson
Marijuana edibles are displayed for sale at the MedMen store in West Hollywood, California U.S. January 2, 2018. REUTERS/Lucy Nicholson
Eron Silverstein, 51, (R) shops for marijuana at the MedMen store in West Hollywood, California U.S. January 2, 2018. REUTERS/Lucy Nicholson
Marijuana products are displayed for sale at the MedMen store in West Hollywood, California U.S. January 2, 2018. REUTERS/Lucy Nicholson
Customers purchase marijuana at Harborside, one of California's largest and oldest dispensary dispensaries of medical marijuana, on the first day of legalized recreational marijuana sales in Oakland, California, U.S., January 1, 2018. REUTERS/Elijah Nouvelage
People wait in line at Harborside, one of California's largest and oldest dispensaries of medical marijuana, on the first day of legalized recreational marijuana sales in Oakland, California, U.S., January 1, 2018. REUTERS/Elijah Nouvelage
A customer waits at the counter to purchase marijuana as others wait in line at Harborside, one of California's largest and oldest dispensaries of medical marijuana, on the first day of legalized recreational marijuana in Oakland, California, U.S., January 1, 2018. REUTERS/Elijah Nouvelage
Andrew DeAngelo (L) and his brother Steve DeAngelo (R), co-founders of Harborside, one of California's largest and oldest dispensaries of medical marijuana, celebrate after a ceremonial ribbon cutting on the first day of legalized recreational marijuana in Oakland, California, U.S., January 1, 2018. REUTERS/Elijah Nouvelage
An employee hugs a customer as others wait in line at Harborside, one of California's largest and oldest dispensaries of medical marijuana, on the first day of legalized recreational marijuana in Oakland, California, U.S., January 1, 2018. REUTERS/Elijah Nouvelage
An employee finds marijuana for a customer at Harborside, one of California's largest and oldest dispensaries of medical marijuana, on the first day of legalized recreational marijuana in Oakland, California, U.S., January 1, 2018. REUTERS/Elijah Nouvelage
Employees wait behind the counter at Harborside, one of California's largest and oldest dispensaries of medical marijuana, as a large clock counts down to the store's official opening at 6am on the first day of legalized recreational marijuana in Oakland, California, U.S. January 1, 2018. REUTERS/Elijah Nouvelage
Different strains of marijuana are seen for sale at Harborside, one of California's largest and oldest dispensaries of medical marijuana, on the first day of legalized recreational marijuana in Oakland, California, U.S., January 1, 2018. REUTERS/Elijah Nouvelage
A couple poses behind a cardboard Instagram frame while waiting in line at Harborside, one of California's largest and oldest dispensaries of medical marijuana, on the first day of legalized recreational marijuana in Oakland, California, U.S., January 1, 2018. REUTERS/Elijah Nouvelage
Employees prepare to open at Harborside, one of California's largest and oldest dispensaries of medical marijuana, on the first day of legalized recreational marijuana in Oakland, California, U.S., January 1, 2018. REUTERS/Elijah Nouvelage
Steve DeAngelo (C) makes the first legal recreational marijuana sale to Henry Wykowski at Harborside, one of California's largest and oldest dispensaries of medical marijuana, on the first day of legalized recreational marijuana sales in Oakland, California, U.S. January 1, 2018. REUTERS/Elijah Nouvelage
Michael Sherman purchases marijuana at Harborside, one of California's largest and oldest dispensaries of medical marijuana, on the first day of legalized recreational marijuana sales in Oakland, California, U.S., January 1, 2018. REUTERS/Elijah Nouvelage
A customer peers at different marijuana strains in a glass case at Harborside, one of California's largest and oldest dispensaries of medical marijuana, on the first day of legalized recreational marijuana in Oakland, California, U.S., January 1, 2018. REUTERS/Elijah Nouvelage
Marijuana is seen for sale at Harborside, one of California's largest and oldest dispensaries of medical marijuana, on the first day of legalized recreational marijuana sales in Oakland, California, U.S., January 1, 2018. REUTERS/Elijah Nouvelage
HIDE CAPTION
SHOW CAPTION
of
SEE ALL
BACK TO SLIDE

In an interview with Business Insider in July, Canopy Growth's CEO, Bruce Linton, explained he wouldn't have chosen just any alcohol brand to work with, but that Constellation's entrepreneurial spirit made it stand out despite its $42 billion market cap.

"Part of the reason we like them isn't just because they're a diversified beverage maker — meaning they do beer, wine, and spirits — but because they're actually entrepreneurial," he said. 

"Why are you having a beverage on a Friday night? It's about a social lubricant. I think they didn't view themselves as a beverage company so much as an entity that provides those occasions with some kind of lift if you will — and that's an easy way to look at cannabis, not as a threat, but as an alternative or additional."

Constellation shares rose about 3.7% in early trading following the announcement. 

For the first quarter of 2019 (ended June 30,2018), Canopy posted a loss of $0.40 a share, far outpacing the $0.11 loss that was expected. Revenue also fell short of the expected $26.33 million, at $25.9 million.

"With our unparalleled success in Canada and Europe, Spectrum Cannabis’ expanding global operational footprint now covering 11 countries, our active regulatory and global market development efforts, as well as approvals to proceed with the first of many planned clinical trials of cannabis-based medical therapies for both humans and animals, our leadership position in international medical cannabis markets continues to strengthen,” Bruce Linton, Canopy’s chief executive, said in a press release.

Linton also said 36% of Canopy’s total supply was now committed to its home country of Canada. When Canada's government voted to legalize marijuana throughout the country earlier this year, Canopy’s stock surged. But in as nascent an industry as cannabis, shares took a 5% hit on Tuesday when the province of Ontario, home of Canada's largest city, said it would delay the roll out of private retail stores.

Wednesday’s gains, if materialized when markets open, could easily take Canopy’s stock price past Wall Street’s $30 target, as high as $37.

Canopy is up 29% this year.

*An earlier version of this article misstated the size of Constellation's $4 billion investment. 

More from Business Insider:  

CANOPY GROWTH STOCKMarkets Insider

Read Full Story

Can't get enough business news?

Sign up for Finance Report by AOL and get everything from retailer news to the latest IPOs delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.